Form 4: Ligand Pharmaceuticals Executive Matthew Korenberg Sells Shares

Matthew Korenberg, President & Chief Operating Officer of Ligand Pharmaceuticals, sold a total of 17,598 shares of common stock in multiple transactions on May 13 and 14, 2024.

Summary

• Matthew Korenberg, President & Chief Operating Officer of Ligand Pharmaceuticals, reported the sale of company stock.
• On May 13, 2024, he sold 3,440 shares of common stock at a weighted average price of $84.5431.
• On May 14, 2024, he sold 13,638 shares at a weighted average price of $85.0826.
• Also on May 14, 2024, he sold 520 shares at a weighted average price of $85.6841.
• Following these transactions, Korenberg directly owns 86,263 shares of Ligand Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, reporting stock sales by an executive. It's neutral in tone and doesn't inherently indicate positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence and are often scrutinized by investors for insights into a company's prospects; however, without additional context, it's difficult to determine the motivation behind these sales.

Stakeholder Impact

• Shareholders may react to the stock sales, potentially influencing the stock price in the short term.
• The impact on employees, customers, suppliers, and creditors is likely minimal unless the sales indicate a larger strategic shift.

Key Dates